Clinical Trial Update: F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for F16IL2 combined with nivolumab in non-small cell lung cancer across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• F16IL2 (F16-IL2)
• nivolumab (nivolumab)

Snippet

Sponsor: Philogen S.p.A. | Conditions: Non-small Cell Lung Cancer (NSCLC) | Phase 1, Phase 2 | Status: UNKNOWN